These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
124 related articles for article (PubMed ID: 7736916)
1. Time- and dose-dependent kinetics of all-trans-retinoic acid in rats after oral or intravenous administration(s). el Mansouri S; Tod M; Leclerq M; Petitjean O; Perret G; Porthault M Drug Metab Dispos; 1995 Feb; 23(2):227-31. PubMed ID: 7736916 [TBL] [Abstract][Full Text] [Related]
3. Variability in the oral bioavailability of all-trans-retinoic acid. Adamson PC; Pitot HC; Balis FM; Rubin J; Murphy RF; Poplack DG J Natl Cancer Inst; 1993 Jun; 85(12):993-6. PubMed ID: 8388479 [TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of the time-dependent elimination of all-trans-retinoic acid in rats. Saadeddin A; Torres-Molina F; Cárcel-Trullols J; Araico A; Peris JE AAPS PharmSci; 2004 Jan; 6(1):E1. PubMed ID: 15198502 [TBL] [Abstract][Full Text] [Related]
5. The area under the concentration-time curve of all-trans-retinoic acid is the most suitable pharmacokinetic correlate to the embryotoxicity of this retinoid in the rat. Tzimas G; Thiel R; Chahoud I; Nau H Toxicol Appl Pharmacol; 1997 Apr; 143(2):436-44. PubMed ID: 9144460 [TBL] [Abstract][Full Text] [Related]
6. Time course of induction of metabolism of all-trans-retinoic acid and the up-regulation of cellular retinoic acid-binding protein. Adamson PC; Boylan JF; Balis FM; Murphy RF; Godwin KA; Gudas LJ; Poplack DG Cancer Res; 1993 Feb; 53(3):472-6. PubMed ID: 8381046 [TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetic properties of ethosuximide in monkeys. I. Single-dose intravenous and oral administration. Patel IH; Levy RH; Bauer TG Epilepsia; 1975 Dec; 16(5):705-16. PubMed ID: 816644 [TBL] [Abstract][Full Text] [Related]
8. Single versus multiple dose administration of all-trans-retinoic acid during organogenesis: differential metabolism and transplacental kinetics in rat and rabbit. Collins MD; Tzimas G; Bürgin H; Hummler H; Nau H Toxicol Appl Pharmacol; 1995 Jan; 130(1):9-18. PubMed ID: 7839374 [TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of 13-cis-, all-trans-, 13-cis-4-oxo-, and all-trans-4-oxo retinoic acid after intravenous administration in the cynomolgus monkey. Sandberg JA; Eckhoff C; Nau H; Slikker W Drug Metab Dispos; 1994; 22(1):154-60. PubMed ID: 8149876 [TBL] [Abstract][Full Text] [Related]
10. Retinoid metabolism and transplacental pharmacokinetics in the cynomolgus monkey following a nonteratogenic dosing regimen with all-trans-retinoic acid. Tzimas G; Nau H; Hendrickx AG; Peterson PE; Hummler H Teratology; 1996 Nov; 54(5):255-65. PubMed ID: 9035347 [TBL] [Abstract][Full Text] [Related]
11. Plasma pharmacokinetics of butyrate after intravenous administration of sodium butyrate or oral administration of tributyrin or sodium butyrate to mice and rats. Egorin MJ; Yuan ZM; Sentz DL; Plaisance K; Eiseman JL Cancer Chemother Pharmacol; 1999; 43(6):445-53. PubMed ID: 10321503 [TBL] [Abstract][Full Text] [Related]
12. Constitutive variability in the pharmacokinetics of the natural retinoid, all-trans-retinoic acid, and its modulation by ketoconazole. Rigas JR; Francis PA; Muindi JR; Kris MG; Huselton C; DeGrazia F; Orazem JP; Young CW; Warrell RP J Natl Cancer Inst; 1993 Dec; 85(23):1921-6. PubMed ID: 8230282 [TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetic study of all-trans-retinoyl-beta-D-glucuronide in Sprague-Dawley rats after single and multiple intravenous administration(s). Lin HS; Barua AB; Olson JA; Low KS; Chan SY; Shoon ML; Ho PC J Pharm Sci; 2001 Dec; 90(12):2023-31. PubMed ID: 11745761 [TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics of oral all-trans retinoic acid in patients with acute promyelocytic leukemia. Lefebvre P; Thomas G; Gourmel B; Agadir A; Castaigne S; Dreux C; Degos L; Chomienne C Leukemia; 1991 Dec; 5(12):1054-8. PubMed ID: 1774953 [TBL] [Abstract][Full Text] [Related]
15. Clinical pharmacology of oral all-trans retinoic acid in patients with acute promyelocytic leukemia. Muindi JR; Frankel SR; Huselton C; DeGrazia F; Garland WA; Young CW; Warrell RP Cancer Res; 1992 Apr; 52(8):2138-42. PubMed ID: 1559217 [TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetic models for the saturable absorption of cefuroxime axetil and saturable elimination of cefuroxime. Ruiz-Carretero P; Merino-Sanjuán M; Nácher A; Casabó VG Eur J Pharm Sci; 2004 Feb; 21(2-3):217-23. PubMed ID: 14757493 [TBL] [Abstract][Full Text] [Related]
18. Assessment of presystemic factors on the oral bioavailability of rifampicin following multiple dosing. Zhang JN; Liu XG; Zhu M; Chiu FC; Li RC J Chemother; 1998 Oct; 10(5):354-9. PubMed ID: 9822352 [TBL] [Abstract][Full Text] [Related]
19. Modulation of all-trans retinoic acid pharmacokinetics by liarozole. Miller VA; Rigas JR; Muindi JR; Tong WP; Venkatraman E; Kris MG; Warrell RP Cancer Chemother Pharmacol; 1994; 34(6):522-6. PubMed ID: 7923564 [TBL] [Abstract][Full Text] [Related]
20. Influence of cholestyramine on the pharmacokinetics of rosiglitazone and its metabolite, desmethylrosiglitazone, after oral and intravenous dosing of rosiglitazone: impact on oral bioavailability, absorption, and metabolic disposition in rats. Muzeeb S; Venkatesh P; Mullangi R; Srinivas NR Xenobiotica; 2006 Sep; 36(9):838-56. PubMed ID: 16971347 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]